Aubrey Rankin - 26 Jul 2021 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
President, Innovation & Tech, Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
26 Jul 2021
Net transactions value
-$1,645,953
Form type
4
Filing time
28 Jul 2021, 21:48:47 UTC
Next filing
30 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale $1,645,953 -55,382 -13% $29.72 355,943 26 Jul 2021 Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 F1, F2, F3
holding RVNC Common Stock 174,302 26 Jul 2021 The Rankin Irrevocable Trust F4
holding RVNC Common Stock 79,776 26 Jul 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
F2 The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.42 to $30.00. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3 These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
F4 These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.